ArticleThe Pan African medical journal2022
Antihyperglycemic effect of
Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Diabetes mellitus in ECOWAS: an overview of the safety and efficacy of medicinal plants used in traditional medicine practices.Tropical medicine and health · 2026Review
- Vernonia amygdalina displays otoprotective effects via antioxidant pathway on cisplatin-induced hair cell loss in zebrafish.Archives of toxicology · 2025Article
- Effects of Black Cumin Seed Extract on Pancreatic Islet β-Cell Proliferation and Hypoglycemic Activity in Streptozotocin-Induced Diabetic Rats.Antioxidants (Basel, Switzerland) · 2025Article
- Awareness, knowledge and belief regarding bitter leaf use: A cross-sectional study in Nigeria.PloS one · 2025Article
- Article
- Bioactive compounds from fermentedIn silico pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: the leaves of Vernonia amygdalina (V. amygdalina) are consumed as food in sub-Saharan Africa (SSA). In traditional medicine, this plant is widely used in the treatment of cancer and diabetes mellitus. In the present study, we evaluated the antihyperglycemic and the antiproliferative activities of the hydroalcoholic extract of V. amygdalina leaves (HAEVa). Methods: we conducted an experimental descriptive and analytical study with a prospective data collection from May 2019 to July 2020. For the in vivo study, the experiments were carried out on albino male rats of Wistar strain (Rattus norvegicus). Antihyperglycemic activity was performed in vivo in dexamethasone-induced insulin-resistant rats using the oral glucose tolerance test (OGTT). The biocompatibility and the antiproliferative activity of extract were performed in vitro respectively on rabbit primary dermal fibroblasts (RPDF) and human osteosarcoma MG-63 cells using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The data were analyzed with the GraphPad Prism software version 5.0.3. The statistical analyses were obtained by the analysis of variance (ANOVA), followed by Bonferroni´s post-test. P<0.05 was considered as the minimal level of statistical significance. Results: regarding to the antiproliferative investigation, extract at 125, 250 μg/mL exhibited a significant cytotoxic effect on human osteosarcoma MG-63 compared to the vehicle (p<0.001) in a dose-response manner after 24h, 48h of exposure to HAEVa. Interestingly, HAEVa in concentrations of 125 and 250μg/ml showed no cytotoxicity (p>0.05) on RPDF after the different times of exposure. However, HAEVa in a high concentration of 500 μg/mL wasn´t biocompatible with RPDF. HAEVa also prevented postprandial blood glucose level in dexamethasone-induced insulin-resistant rats at both doses tested (p>0.05 and p<0.01 at doses of 50 and 100 mg/kg respectively). Conclusion: the results of this study suggest that HAEVa has antiproliferative properties on MG-63 osteosarcoma in vitro and also inhibits in vivo the postprandial blood glucose level in dexamethasone-induced insulin-resistant rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.